Skip to main content
. Author manuscript; available in PMC: 2023 Jul 3.
Published in final edited form as: J Bone Miner Metab. 2020 Jan 25;38(4):544–554. doi: 10.1007/s00774-019-01081-1

Fig. 1.

Fig. 1

Resorption bone turnover marker in combined oral contraceptive (COC) users and non-COC users. Data are presented for study entry (0 months), 6, and 12 months in young females. CTX is C-terminal telopeptides. COC users have significantly greater CTX at study entry (*P = 0.02) and 6 months (#P = 0.018) compared to non-COC users